PROSTAGLANDINS, THE KIDNEY AND HYPERTENSION
前列腺素、肾脏和高血压
基本信息
- 批准号:2215605
- 负责人:
- 金额:$ 37.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-09-01 至 1999-08-31
- 项目状态:已结题
- 来源:
- 关键词:adenylate cyclase adrenergic agents angiotensin II antihypertensive agents calcium endothelin gas chromatography glomerular filtration high performance liquid chromatography kidney circulation kidney metabolism kidney transplantation leukotrienes mass spectrometry nephrotic syndrome platelet activating factor prostaglandins radioimmunoassay renal glomerulus renal hypertension renal medulla salt intake spontaneous hypertensive rat thin layer chromatography thromboxanes tissue /cell culture vascular resistance vasopressins
项目摘要
We propose experiments to study glomerular mesangial cells, in
culture, in order to evaluate membrane receptors and signal
transduction pathways activated by the vasoconstrictors, endothelin
(ET) and thromboxane A2 (TxA2). We will quantitate receptor
number, affinity and specificity and correlate receptor
characteristics with cellular responses to these ligands. We will
also evaluate the role of GTP binding proteins to link receptors
to plasma membrane enzymes such as adenylate cyclase and
phospholipases A, C and D. The role of G proteins will be measured
in both intact cells and with cell membranes using stable GTP
analogues. The capacity of phospholipase D to mediate cellular
responses to ET and TxA2 will be studied as will the possibility
that phospholipase C will use phospholipid substrates in addition
to polyphosphoinositides. In subsequent studies, we will evaluate
the importance of these signal transduction pathways to mediate the
cellular responses of contraction and proliferation. Specifically,
we will attempt to mimic proliferative and contractile actions of
ET and TxA2 through changes of cellular inositol phosphates,
(Ca2+)i pHi and protein kinase C activity. We will also attempt
to dissociate phospholipase C activation from the membrane receptor
through EJ-ras transfection of the mesangial cells. These
manipulations will allow dissection of the relative importance of
these signal transduction events either singly or in combination
to mediate mesangial contraction and proliferation. Finally, we
will search for a genetic defect of mesangial and vascular smooth
muscle cells in genetically hypertensive strains. We propose that
hyperresponsiveness of the phospholipase C signalling pathways may
mediate enhanced vasoconstriction and reduced glomerular
filtration. This theory will be tested using cultured vascular
smooth muscle and mesangial cells with an assessment not only of
their contractile and proliferative responses to contractile
agonists but also a comparison of phospholipase C activation with
measurements of (Ca2+)i, pHi, release of inositol phosphates and
stimulation of protein kinase C.
我们建议实验研究肾小球系膜细胞,
培养,以评估膜受体和信号
由血管收缩剂内皮素激活的转导通路
(ET)和血栓素A2(TxA 2)。 我们将定量受体
数量、亲和力和特异性以及相关受体
这些特征与细胞对这些配体的反应有关。 我们将
还评估GTP结合蛋白连接受体的作用
质膜酶如腺苷酸环化酶和
磷脂酶A、C和D。 G蛋白的作用将被测量
在完整细胞和细胞膜中使用稳定的GTP
类似物 磷脂酶D介导细胞凋亡的能力
将研究对ET和TxA 2的反应,
磷脂酶C将使用磷脂底物,
到聚磷酸肌醇。 在接下来的研究中,我们将评估
这些信号转导通路的重要性,以介导
收缩和增殖的细胞反应。 具体地说,
我们将尝试模拟
ET和TxA 2通过改变细胞磷酸肌醇,
(Ca2+)i pHi和蛋白激酶C活性。 我们还将尝试
使磷脂酶C活化与膜受体分离
通过EJ-ras转染系膜细胞。 这些
操作将允许解剖的相对重要性,
这些信号转导事件或者单独地或者组合地
介导系膜收缩和增殖。 最后我们
将寻找系膜和血管平滑的遗传缺陷
肌肉细胞的遗传性高血压菌株。 我们建议
磷脂酶C信号通路的高反应性可能
介导增强血管收缩和减少肾小球
过滤 这一理论将用培养的血管
平滑肌和系膜细胞,不仅评估
它们的收缩和增殖反应,
激动剂,但也比较磷脂酶C激活与
测量(Ca 2+)i、pHi、肌醇磷酸的释放和
刺激蛋白激酶C。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL J DUNN其他文献
MICHAEL J DUNN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL J DUNN', 18)}}的其他基金
VISION RES LAB: HERPETIC KERATIC, CORE PIGMENT GENES, RETINITIS PIGMENTOSA
VISION RES 实验室:疱疹性角化病、核心色素基因、色素性视网膜炎
- 批准号:
6794430 - 财政年份:2002
- 资助金额:
$ 37.17万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 37.17万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 37.17万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 37.17万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 37.17万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 37.17万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 37.17万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 37.17万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 37.17万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 37.17万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 37.17万 - 项目类别: